Medicus Pharma Ltd. Common Stock
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Raza Bokhari
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 300 Conshohocken State Road West Conshohocken PA Canada 19428
- IPO Date
- Nov 15, 2024
- CIK
- 0001997296
- Website
- medicuspharma.com
- Similar Companies
- Business
- Medicus Pharma Ltd. (NASDAQ:MDCX) is a biotech and life sciences company that focuses on accelerating the clinical development and commercialization of novel and disruptive therapeutic assets through acquisitions, partnerships and targeted investments. The company develops SkinJect, a patented dissolvable doxorubicin-containing microneedle array (D-MNA) as a non-invasive treatment for basal cell carcinoma and other non-melanoma skin cancers via ongoing Phase 2 trials including SKNJCT-003 in the United States and Europe and SKNJCT-004 in the United Arab Emirates; through its August 2025 acquisition of Antev Limited, it now advances Teverelix trifluoroacetate, a next-generation long-acting GnRH antagonist formulated as a microcrystalline suspension for sustained release every six weeks to treat acute urinary retention relapse in enlarged prostate patients and advanced prostate cancer in high cardiovascular-risk individuals, with FDA-approved Phase 2b study designs for 390 and 40 patients respectively. Medicus Pharma operates across three continents with clinical activities in the United States, United Kingdom, United Arab Emirates and Europe; founded in 2008, it maintains headquarters in Conshohocken, Pennsylvania, with prior Canadian operations in Toronto. Recent developments include the September 2025 acquisition of 98.6% of Antev for $2.97 million in cash plus 1.6 million shares and up to $65 million in contingent milestone payments tied to FDA approvals, adding Teverelix and industry veteran Patrick J. Mahaffy to its board; a strategic October 2025 collaboration with the Gorlin Syndrome Alliance to pursue FDA Expanded Access for SkinJect in patients with multiple recurrent basal cell carcinomas; an August 2025 non-binding memorandum of understanding with Helix Nanotechnologies to explore co-development of thermostable mRNA infectious disease vaccines combining microneedle delivery; positive FDA Type C meeting feedback in September 2025 supporting the 505(b)(2) pathway for SkinJect; full UK regulatory approvals in November 2025 to expand SKNJCT-003; and first patient dosing in SKNJCT-004. Subsidiaries include SkinJect Inc. and Antev Limited, with operations targeting unmet needs in oncology and urology for improved patient safety, efficacy and compliance.
Company News
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Medicus Pharma advances pipeline during Q2 with key milestones
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
SK Hynix backed by Wedbush as memory undersupply persists
Medicus Pharma CMO to lead Antev's Teverelix clinical programme
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
Medicus Pharma targets Gorlin Syndrome with SkinJect - ICYMI
Medicus Pharma targets Gorlin Syndrome with SkinJect - ICYMI
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix
Roblox shares plummet on revenue miss, withdrawn guidance
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
Reddit shares slump after management warns of search traffic volatility despite strong earnings beat
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix
Honeywell upgraded by Bank of America on stronger order trends
Medicus Pharma receives FDA clearance to begin registrational SkinJect study for Gorlin syndrome
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
Nvidia in talks to back OpenAI data center financing with $250B guarantee, WSJ reports
Medicus Pharma CEO details Teverelix progress – ICYMI
Medicus Pharma CEO details Teverelix progress – ICYMI
Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval